Biosimilars were introduced with the promise of expanding access to biologic therapies while reducing healthcare costs. As more blockbuster biologics lose exclusivity, biosimilars are becoming an incr...
For decades, women’s health remained one of the most underfunded and underserved areas in healthcare despite representing half the global population. Many conditions affecting women received limited r...
Takeaways: Felix is positioning itself as the price‑breaker in Canada’s GLP‑1 obesity market, using cheaper semaglutide (as generics arrive) to tackle the main dropout driver and convert strong ...
Contract development and manufacturing organizations, often referred to as CDMOs, were once viewed primarily as outsourced service providers supporting pharmaceutical production. Today, their role is ...
As the pharmaceutical industry becomes increasingly digital, cybersecurity is emerging as one of the sector’s most urgent and underestimated risks. Clinical trials, manufacturing operations, supply ch...
For decades, oncology innovation has focused primarily on developing more effective treatments for advanced disease. Today, however, the industry is beginning to shift toward a new frontier: detecting...
Precision medicine is often defined by breakthrough therapies and targeted treatments, but behind many of these advances lies a less visible yet increasingly essential component: companion diagnostics...
The pharmaceutical industry has long occupied a complex position in public perception, celebrated for life saving innovation yet frequently criticized for pricing practices, transparency concerns, and...
The COVID-19 pandemic fundamentally transformed the global vaccine industry, accelerating scientific innovation, manufacturing investment, and public awareness at an unprecedented pace. Technologies t...
Rare diseases were once considered commercially unattractive due to their limited patient populations and high development costs. Today, however, they have become one of the fastest growing areas of i...













